Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562634 | 0.81 | ROCK2 (0.61) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL1105177 | 0.81 | ROCK2 (0.61) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL1105178 | 0.81 | ROCK2 (0.61) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL13764113 | 0.77 | ROCK2 (0.67) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL1105182 | 0.74 | ROCK2 (0.45) | ROCK2ROCK1NOTUMIMPDH2 | |
| SCHEMBL14562639 | 0.74 | ROCK2 (0.45) | ROCK2ROCK1NOTUMIMPDH2 | |
| SCHEMBL14562568 | 0.72 | ROCK2 (0.63) | ROCK2ROCK1NOTUMIMPDH2 | |
| SCHEMBL1123656 | 0.72 | ROCK2 (0.63) | ROCK2ROCK1NOTUMIMPDH2 | |
| SCHEMBL1105023 | 0.71 | ROCK2 (0.48) | ROCK2ROCK1NOTUMCACNA2D1IMPDH2 | |
| SCHEMBL1105030 | 0.71 | ROCK2 (0.47) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871757-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455514-B2 | 6-and 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-2546237-A1 | 7-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546239-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2546238-A1 | 6-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8153654-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-8153654-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009091898-A2 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | AERIE PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144713-A1 | 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | COQ8A, MAP3K7, PRKG2 | ROCK2 214/4885ROCK1 304/4885NOTUM 2328/4885 |
| US-20090186917-A1 | 6-And 7-amino isoquinoline compounds and methods for making and using the same | COQ8A, MAP3K7, PRKG2 | ROCK2 214/4885ROCK1 304/4885NOTUM 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.